Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER vs AMINOSOL 5%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Travasol 2.75% with electrolytes in dextrose 15% is a parenteral nutrition formulation. It provides amino acids for protein synthesis, dextrose for caloric energy, and electrolytes for maintaining homeostasis. Dextrose stimulates insulin release and provides glucose for cellular metabolism. Amino acids are utilized for tissue repair and nitrogen balance. Electrolytes maintain acid-base balance, neuromuscular function, and enzymatic processes.
Aminosyl 5% is a parenteral amino acid solution that provides essential and non-essential amino acids for protein synthesis, tissue repair, and maintenance of nitrogen balance in patients unable to tolerate enteral feeding.
Parenteral nutrition for patients who cannot obtain adequate nutrition orally or enterally,Off-label: Adjunctive therapy in catabolic states (e.g., burns, trauma, sepsis)
Total parenteral nutrition in patients with inadequate oral or enteral intake,Correction of negative nitrogen balance in malnourished patients
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER is a total parenteral nutrition (TPN) solution. Adult dosing is based on caloric and protein needs: typically 1-2 L/day intravenously, providing 15% dextrose (150 g/L) and 2.75% amino acids (27.5 g/L). Infusion rate initially 1.5-2 m L/min, adjusted to meet metabolic requirements.
Intravenous infusion: 500 m L to 1 L of 5% solution over 8-12 hours, providing 25-50 g of amino acids. Maximum infusion rate: 0.1 g/kg/hour. Dose based on metabolic requirements and clinical status.
Not applicable (mixture of nutrients with endogenous clearance). Glucose: ~1-2 h; amino acids: ~0.5-2 h; electrolytes: vary.
The half-life of infused amino acids is not defined as they are endogenous compounds. However, the nitrogen from amino acids has a biological half-life of approximately 6-18 hours, depending on metabolic activity. As part of total parenteral nutrition, the elimination half-life of infused amino acids is influenced by protein turnover and catabolism.
Metabolized via amino acid oxidation and gluconeogenesis in the liver and kidneys. Dextrose undergoes glycolysis and oxidative phosphorylation. Electrolytes are not metabolized but excreted or retained as needed.
Amino acids are metabolized primarily in the liver via transamination, deamination, and urea cycle. Excretion of nitrogenous waste as urea occurs renally.
Renal: 100% (as glucose, amino acids, and electrolytes). Biliary/fecal: negligible.
Excretion of infused amino acids is primarily renal, with small amounts lost via feces and skin. Approximately 85-95% of the nitrogen load is excreted in urine as urea, ammonia, and other nitrogenous wastes. Less than 5% is eliminated in feces.
None for components. Amino acids: minimal (<10%).
Amino acids are not protein-bound; they exist free in plasma. Minimal reversible binding to albumin occurs for some amino acids, but overall binding is <10%.
Not applicable as a mixture; individual components distribute into total body water (0.6 L/kg) or extracellular fluid (0.2 L/kg).
The volume of distribution for amino acids is approximately 0.3-0.4 L/kg, reflecting distribution primarily in extracellular fluid and to a lesser extent intracellularly.
Intravenous: 100% (only route).
Intravenous: 100% bioavailability. Not administered via other routes; oral or enteral administration is not applicable due to hepatic first-pass metabolism and different pharmacokinetics.
In renal impairment (GFR <30 m L/min): restrict fluid and electrolytes; use specialized amino acid formulations (e.g., essential amino acid solutions). Dextrose content may cause hyperglycemia; monitor glucose. Reduce volume and electrolytes as needed. For non-dialysis patients, avoid unless specific benefits outweigh risks.
In GFR < 50 m L/min: reduce infusion rate by 50% and monitor nitrogen balance. In ESRD on dialysis: use only if essential; typical dose 0.5-0.6 g/kg/day of amino acids with careful monitoring.
In hepatic impairment (Child-Pugh class B or C): monitor for encephalopathy; amino acid load may precipitate hepatic encephalopathy. Use lower protein intake (0.6-0.8 g/kg/day) or branched-chain amino acid enriched solutions. Dextrose may exacerbate hyperglycemia; adjust insulin as needed.
Contraindicated in severe hepatic failure (Child-Pugh C) due to risk of hepatic encephalopathy. In Child-Pugh A or B, use with caution and reduce dose by 30-50%; monitor ammonia levels.
Weight-based: neonates 1-3 g/kg/day amino acids, up to 15 g/kg/day dextrose, titrated. Infants and children: 1-2 g/kg/day amino acids, 10-20% dextrose at 1-2 m L/kg/hour. Adjust electrolytes per serum levels. Use age-specific formulations; monitor growth and metabolic parameters.
Infants and children: 1-2 g/kg/day of amino acids via total parenteral nutrition (TPN) as a 5% solution. Adjust based on age, weight, and clinical condition. Maximum infusion rate 0.1 g/kg/hour.
Elderly: start at lower volume (0.5-1 L/day) due to reduced renal function and fluid reserve. Monitor glucose and electrolytes closely; dextrose load may require insulin. Amino acid dosing per protein requirements (1-1.2 g/kg/day if no renal impairment). Adjust for comorbidities.
Start at lower end of dosing; monitor renal function (creatinine clearance) and avoid fluid overload. Typical initial dose: 0.8-1 g/kg/day of amino acids, adjusted to tolerance and clinical response.
Not for intravenous injection as a sole source of nutrition. Contains aluminum that may be toxic. Use with caution in renal impairment due to aluminum accumulation. Do not administer unless solution is clear and container undamaged.
None.
Risk of hyperglycemia, especially in diabetic patients,Electrolyte imbalances (hyperkalemia, hypophosphatemia, etc.),Volume overload in patients with heart failure or renal disease,Aluminum toxicity with prolonged use, especially in renal impairment,Thrombophlebitis and infection at infusion site,Refeeding syndrome in malnourished patients
Use with caution in patients with renal impairment (risk of azotemia and electrolyte imbalances),Monitor serum electrolytes, blood glucose, and fluid balance regularly,Risk of hyperglycemia in diabetic patients; adjust insulin accordingly,Possible hyperammonemia, especially in patients with hepatic insufficiency,Contains aluminum; may accumulate in renal impairment, leading to osteomalacia or neurotoxicity
Anuria or severe renal impairment without appropriate monitoring,Inborn errors of amino acid metabolism (e.g., phenylketonuria),Severe electrolyte disorders before correction,Hyperglycemia uncontrolled by insulin,Hypersensitivity to any component
Severe hepatic failure with encephalopathy,Severe uremia without dialysis,Inborn errors of amino acid metabolism,Hypersensitivity to any component
None; parenteral nutrition bypasses gastrointestinal tract. However, monitor oral intake if transitioning to enteral nutrition.
No direct food interactions as Aminos 5% is administered intravenously. However, oral dietary intake must be coordinated with total parenteral nutrition to avoid excessive protein or electrolyte intake.
No adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Parenteral nutrition is essential in certain conditions; use only if clearly needed. Potential fetal risks include metabolic disturbances (e.g., hyperglycemia, electrolyte imbalances) associated with maternal administration of dextrose and electrolytes, which may affect fetal homeostasis. However, no specific teratogenic effects have been documented.
Aminosol 5% is a crystalline amino acid solution used for parenteral nutrition. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted with Aminosol 5%. Therefore, the teratogenic risk is not well defined. However, as a component of parenteral nutrition, it is considered essential for maternal and fetal health when indicated. Use only if clearly needed, weighing potential benefits against unknown risks. No specific trimester-associated risks have been reported.
It is not known whether components of this solution are excreted in human milk. No M/P ratio available. Caution should be exercised when administered to a breastfeeding woman. The high dextrose content may affect maternal glucose levels, indirectly influencing milk composition. Consider the benefits of breastfeeding and the importance of the drug to the mother.
Aminosolic 5% is a mixture of amino acids naturally present in human milk. Administration to lactating women may result in excretion of amino acids into breast milk, but the amounts are unlikely to be clinically significant. The M/P ratio is not known. Caution is advised, but use is generally considered compatible with breastfeeding when clinically indicated.
Pharmacokinetic changes in pregnancy may require dose adjustments: increased plasma volume and glomerular filtration rate may alter electrolyte and fluid balance; increased insulin resistance may necessitate modifications in dextrose delivery. Monitor glycemic control and adjust dextrose infusion rate accordingly. Electrolyte requirements may change; adjust based on serum levels. No specific dosing guidelines are established; individualize based on maternal clinical status and laboratory parameters.
Standard adult dosing (5% solution, 500-1000 m L/day) may be used; however, increased fluid volume and metabolic demands in pregnancy may require dose adjustments. Monitor for fluid overload and adjust infusion rate accordingly. No specific dose adjustment recommendations are established; use caution and individualize based on clinical status.
Contains 2.75% amino acids, 15% dextrose, and electrolytes. Ensure central line access for high osmolality (approx. 1450 m Osm/L). Monitor serum electrolytes, glucose, and fluid status. Avoid in patients with severe metabolic alkalosis or anuria. Contains sulfite, may cause allergic reactions in asthmatics.
Aminos 5% is a crystalline amino acid solution used for parenteral nutrition. In renal failure, adjust dose to limit nitrogen load; monitor BUN. In hepatic encephalopathy, consider branched-chain amino acid formulations. Do not administer concurrently with blood products through same IV line due to risk of agglutination. Infuse via central line if peripheral veins insufficient; peripheral administration requires adequate lipid-based calorie co-administration to prevent phlebitis.
This solution provides nutrition and fluids directly into your vein.,Your blood sugar and electrolyte levels will be monitored regularly.,Report any signs of infection at the IV site like redness, swelling, or warmth.,Do not stop or adjust the infusion rate yourself.
This solution provides essential building blocks (amino acids) for protein synthesis when you cannot eat.,Report any signs of infection at the IV site: redness, swelling, pain, or drainage.,Tell your doctor if you experience nausea, vomiting, or headache; dose adjustment may be needed.,Do not abruptly stop this infusion; it is part of your total nutrition plan.,Regular blood tests will be required to monitor kidney and liver function.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER vs AMINOSOL 5%, answered by our medical review team.
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER is a Parenteral Nutrition Solution that works by Travasol 2.75% with electrolytes in dextrose 15% is a parenteral nutrition formulation. It provides amino acids for protein synthesis, dextrose for caloric energy, and electrolytes for maintaining homeostasis. Dextrose stimulates insulin release and provides glucose for cellular metabolism. Amino acids are utilized for tissue repair and nitrogen balance. Electrolytes maintain acid-base balance, neuromuscular function, and enzymatic processes.. AMINOSOL 5% is a Parenteral Nutrition Solution that works by Aminosyl 5% is a parenteral amino acid solution that provides essential and non-essential amino acids for protein synthesis, tissue repair, and maintenance of nitrogen balance in patients unable to tolerate enteral feeding.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER and AMINOSOL 5% depend on the specific clinical indication. These are both Parenteral Nutrition Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER is: TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER is a total parenteral nutrition (TPN) solution. Adult dosing is based on caloric and protein needs: typically 1-2 L/day intravenously, providing 15% dextrose (150 g/L) and 2.75% amino acids (27.5 g/L). Infusion rate initially 1.5-2 m L/min, adjusted to meet metabolic requirements.. The standard adult dose of AMINOSOL 5% is: Intravenous infusion: 500 m L to 1 L of 5% solution over 8-12 hours, providing 25-50 g of amino acids. Maximum infusion rate: 0.1 g/kg/hour. Dose based on metabolic requirements and clinical status.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER and AMINOSOL 5% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER is classified as Category C. No adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Parenteral nutrition is essential in certain conditions; use only if. AMINOSOL 5% is classified as Category C. Aminosol 5% is a crystalline amino acid solution used for parenteral nutrition. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies hav. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.